文献速递眼底病与葡萄膜炎

玻璃体腔雷珠单抗与全视网膜光凝治疗增殖性糖尿病视网膜病变的五年随机临床试验结果

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

该多中心随机临床试验纳入394只增殖性糖尿病视网膜病变(PDR)眼,比较0.5 mg玻璃体腔雷珠单抗与全视网膜光凝(PRP)的5年疗效与安全性。结果显示两组视力变化相似,雷珠单抗组视力损害性糖尿病黄斑水肿发生率更低且视野损失更少,主要全身不良事件率无显著差异。

要点

  • 雷珠单抗组视力损害性糖尿病黄斑水肿累积概率22%,低于PRP组的38%(HR 0.4;95%CI 0.3-0.7)。
  • 两组主要全身不良事件率无统计学显著差异,严重视力丧失或PDR严重并发症均不常见。

核心结论

  • 完成随访的大多数研究眼在5年时视力很好且两组相似,雷珠单抗组视力损害性糖尿病黄斑水肿发生率更低且视野损失更少。

研究设计与样本

  • Diabetic Retinopathy Clinical Research Network多中心随机临床试验,2012年2月至12月纳入394只PDR研究眼,随机分配至玻璃体腔雷珠单抗0.5 mg组(n=191)或PRP组(n=203)。

主要发现

  • 雷珠单抗组与PRP组5年平均注射次数分别为19.2和5.4次。
  • 5年时两组平均视力均约为20/25(近似Snellen等效值)。
  • 雷珠单抗组(n=41)与PRP组(n=38)累积视野总点分平均变化分别为-330 dB和-527 dB(校正差异208 dB;95%CI 9-408)。
  • 雷珠单抗组与PRP组分别有27只眼和53只眼发生视力损害性糖尿病黄斑水肿(累积概率22% vs 38%;HR 0.4;95%CI 0.3-0.7)。

关键数值与推荐

  • 雷珠单抗注射频率依据方案规定的再治疗算法。
  • 任一组糖尿病黄斑水肿均可使用雷珠单抗管理。
  • 主要结局为视力平均变化(意向性治疗分析)。

临床怎么用

  • 选择PDR治疗方案时应考虑患者特异性因素,包括预期就诊依从性、费用和就诊频率。
  • 这些发现支持抗血管内皮生长因子(VEGF)治疗或PRP作为PDR患者的可行治疗选择。

局限性

  • 失访率相对较高(5年访视完成者占排除死亡后277名参与者的66%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ranibizumab is a viable treatment option for eyes with proliferative diabetic retinopathy (PDR) through 2 years. However, longer-term results are needed. OBJECTIVE: To evaluate efficacy and safety of 0.5-mg intravitreous ranibizumab vs panretinal photocoagulation (PRP) over 5 years for PDR. DESIGN, SETTING, AND PARTICIPANTS: Diabetic Retinopathy Clinical Research Network multicenter randomized clinical trial evaluated 394 study eyes with PDR enrolled February through December 2012. Analysis began in January 2018. INTERVENTIONS: Eyes were randomly assigned to receive intravitreous ranibizumab (n = 191) or PRP (n = 203). Frequency of ranibizumab was based on a protocol-specified retreatment algorithm. Diabetic macular edema could be managed with ranibizumab in either group. MAIN OUTCOMES AND MEASURES: Mean change in visual acuity (intention-to-treat analysis) was the main outcome. Secondary outcomes included peripheral visual field loss, development of vision-impairing diabetic macular edema, and ocular and systemic safety. RESULTS: The 5-year visit was completed by 184 of 277 participants (66% excluding deaths). Of 305 enrolled participants, the mean (SD) age was 52 (12) years, 135 (44%) were women, and 160 (52%) were white. For the ranibizumab and PRP groups, the mean (SD) number of injections over 5 years was 19.2 (10.9) and 5.4 (7.9), respectively; the mean (SD) change in visual acuity letter score was 3.1 (14.3) and 3.0 (10.5) letters, respectively (adjusted difference, 0.6; 95% CI, -2.3 to 3.5; P = .68); the mean visual acuity was 20/25 (approximate Snellen equivalent) in both groups at 5 years. The mean (SD) change in cumulative visual field total point score was -330 (645) vs -527 (635) dB in the ranibizumab (n = 41) and PRP (n = 38) groups, respectively (adjusted difference, 208 dB; 95% CI, 9-408). Vision-impairing diabetic macular edema developed in 27 and 53 eyes in the ranibizumab and PRP groups, respectively (cumulative probabilities: 22% vs 38%; hazard ratio, 0.4; 95% CI, 0.3-0.7). No statistically significant differences between groups in major systemic adverse event rates were identified. CONCLUSIONS AND RELEVANCE: Although loss to follow-up was relatively high, visual acuity in most study eyes that completed follow-up was very good at 5 years and was similar in both groups. Severe vision loss or serious PDR complications were uncommon with PRP or ranibizumab; however, the ranibizumab group had lower rates of developing vision-impairing diabetic macular edema and less visual field loss. Patient-specific factors, including anticipated visit compliance, cost, and frequency of visits, should be considered when choosing treatment for patients with PDR. These findings support either anti-vascular endothelial growth factor therapy or PRP as viable treatments for patients with PDR. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01489189.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gross JG, Glassman AR, Liu D, et al. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2018. PMID: 30043039. doi:10.1001/jamaophthalmol.2018.3255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。